Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.

HalioDx's Immunoscore test, which measures host immune response at the tumor site, will be used to select patients for the trial.

The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.

The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.

The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.

The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.

The report noted that savings from the lower payment rates were offset by increased spending on other tests, including genetic tests.

The firm's US clinical trials came to a standstill in the second quarter, affecting its post-approval study for the Epi proColon colorectal cancer liquid-biopsy test.

The company was able to ramp up recruitment for its pivotal ECLIPSE trial after hurdles caused a falloff during the earlier months of the COVID-19 pandemic.

The company believes the pandemic will accelerate the adoption of its cancer diagnostics as patients and doctors look for faster and more convenient tests.

Pages